Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA) (SAR-FAME)

Fundación Andaluza de Reumatología

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Other

Identifiers

NCT02094326

SAR-FAM-2013-01

Details and patient eligibility

About

The purpose of this study is to find patterns in the use of non-biological DMARDs as the initial treatment of RA and how adverse events (AEs), intolerance or lack of efficacy may impact therapeutic decisions in real life in the Spanish Andalusian region.

Enrollment: 301 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of both sexes ≥ 18 years.
• Patients diagnosed with RA (according to the American College of Rheumatology (ACR) 2010 criteria) between January 2008 and December 2012 and who have initiated treatment with at least one synthetic DMARD during that period.
• Patients who have given written informed consent for their data to be collected and reviewed.

Exclusion criteria

• Patients who are already participating in a clinical trial/s at the moment of participation in this study.
• Patients with whom it is suspected there will be insufficient information to complete the study objectives.